Presenter of 1 Presentation
CREATING CLINICALLY COMPETITIVE FLASH PROTON THERAPY TREATMENT PLANS
Abstract
Background and Aims
FLASH proton therapy (FLASH-PT) is beginning the transition into clinical practice. The beam delivery, dose rates, and fractionation schemes for FLASH-PT differ from standard radiotherapy. Hence, no guidelines exist regarding the development of treatment plans for this novel technique. This study aims to determine if FLASH-PT treatment plans can be developed and if the in silico results are comparable to the treatment plans produced for standard radiotherapy.
Methods
FLASH-PT and IMPT treatment plans were created using a novel research version of the MIROpt TPS, developed by Ion Beam Applications SA from the open source version of UCLouvain, for nine patient cases of bone (3), brain (3), and lung metastases (3), previously clinically treated with 3DCRT or VMAT. A FLASH proton dose rate of ≥ 40 Gy/s was included as an optimisation criterion for each patient case. Treatment plans were compared using dose volume histograms (DVHs), boxplots, and the Wilcoxon Rank Sum Test with a 5% significance level and using DVH parameters V100%, V95%, V50%, D99%, D95%, and D2% for target and body structures.
Results
No significant differences were found between the optimised FLASH-PT plans and the clinical 3DCRT/VMAT and optimised IMPT plans.
Conclusions
The FLASH-PT treatment plans created in this study produced in silico results comparable to those of clinically competitive treatment plans. Future work involves the verification of the calculated dose against delivered dose and dose rate, to ensure that the produced treatment plans can be delivered safely and accurately, confirming the feasibility of the clinical implementation of conformal FLASH-PT.
Author Of 1 Presentation
CREATING CLINICALLY COMPETITIVE FLASH PROTON THERAPY TREATMENT PLANS
Abstract
Background and Aims
FLASH proton therapy (FLASH-PT) is beginning the transition into clinical practice. The beam delivery, dose rates, and fractionation schemes for FLASH-PT differ from standard radiotherapy. Hence, no guidelines exist regarding the development of treatment plans for this novel technique. This study aims to determine if FLASH-PT treatment plans can be developed and if the in silico results are comparable to the treatment plans produced for standard radiotherapy.
Methods
FLASH-PT and IMPT treatment plans were created using a novel research version of the MIROpt TPS, developed by Ion Beam Applications SA from the open source version of UCLouvain, for nine patient cases of bone (3), brain (3), and lung metastases (3), previously clinically treated with 3DCRT or VMAT. A FLASH proton dose rate of ≥ 40 Gy/s was included as an optimisation criterion for each patient case. Treatment plans were compared using dose volume histograms (DVHs), boxplots, and the Wilcoxon Rank Sum Test with a 5% significance level and using DVH parameters V100%, V95%, V50%, D99%, D95%, and D2% for target and body structures.
Results
No significant differences were found between the optimised FLASH-PT plans and the clinical 3DCRT/VMAT and optimised IMPT plans.
Conclusions
The FLASH-PT treatment plans created in this study produced in silico results comparable to those of clinically competitive treatment plans. Future work involves the verification of the calculated dose against delivered dose and dose rate, to ensure that the produced treatment plans can be delivered safely and accurately, confirming the feasibility of the clinical implementation of conformal FLASH-PT.